Skip to main content

Clifford Chance

Clifford Chance
Paul Lakkis

Paul Lakkis


Paul Lakkis

Paul Lakkis focuses his practice on corporate and securities matters, primarily representing US and foreign issuers and investment banks in public and private corporate finance transactions. His experience includes working on initial public offerings, follow-on offerings, at-the-market offerings, and Rule 144A offerings. Paul has advised companies in the healthcare, life science, biotechnology, real estate finance, and manufacturing industries. Paul also counsels public companies in connection with annual and quarterly reports, proxy statements, and compliance under US federal securities laws.

Paul’s recent experience* includes advising:

  • Eli Lilly and Company (NYSE: LLY) in its tender offer and acquisition of Sigilon Therapeutics, Inc., for a purchase price of US$14.92 per share in cash (approximately US$34.6 million), plus a contingent value right that entitled the Sigilon stockholders to receive up to an additional US$111.64 in cash upon the achievement of future milestones, for an aggregate purchase price of up to approximately US$309.6 million.
  • Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as joint book-running managers of a US$230 million upsized underwritten public offering of common stock by Revance Therapeutics, Inc. (Nasdaq: RVNC), which included the full exercise of the option to purchase additional shares by Goldman Sachs, Cowen and Guggenheim. Revance is a biotechnology company focused on elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings.
  • Zurn Water Solutions Corp. (NYSE: ZWS) in its acquisition of Elkay Manufacturing Co. in an all-stock transaction that valued Elkay at US$1.56 billion. The deal required the filing of a Form S-4. Zurn is a market leader in smart, sustainable water solutions and products.
  • 23andMe Holding Co. (Nasdaq: ME) in its filing of a US$500 million shelf registration statement on Form S-3 and the establishment of an at-the-market (ATM) public offering program for up to US$150 million of Class A common stock.
  • PTC Therapeutics, Inc. (Nasdaq: PTCT) in its filing of a resale registration statement on Form S-3ASR.
  • Selina Hospitality PLC (Nasdaq: SLNA), a global hospitality brand, in its merger with BOA Acquisition Corp., a publicly traded special purpose acquisition company.
  • Rexnord Corp. in its merger with Regal Beloit Corp., under which Rexnord separated its Process & Motion Control (PMC) segment by way of a tax-free spin-off to Rexnord shareholders and then was combined with Regal in a Reverse Morris Trust (RMT) transaction. The RMT transaction included the filing of a Form S-4. With the addition of PMC, Regal’s 2020 pro forma revenue was approximately US$4.1 billion, and the resulting merger resulted in a US$10 billion public PMC business (NYSE: RRX).
  • Cowen & Company, LLC as sales agent in a new US$150 million at-the-market (ATM) public offering of common shares of Revance Therapeutics Inc. (Nasdaq: RVNC) pursuant to a shelf registration statement on Form S-3.
  • uniQure N.V. (Nasdaq: QURE), a clinical-stage biotechnology company, in its registered US$250 million follow-on public offering of ordinary shares, which included the full exercise of the underwriters’ option to purchase additional shares.

*Prior to joining Clifford Chance in 2023.

News and client work

View all news and client work featuring Paul Lakkis

Contact details

Career and qualifications

  • California State University, BS, Business Administration and Entrepreneurship, 2015
  • Boston College Law School, J.D., 2018
  • Admitted as attorney-at-law in Massachusetts, 2018
  • Admitted as attorney-at-law in New York, 2020
  • Joined Clifford Chance 2023